News | March 06, 2009

Atritech to Release PROTECT AF Trial Results at ACC

March 6, 2009 - Atritech Inc. will release PROTECT AF trial results on WATCHMAN LAA closure technology comparing the device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation.

The results will be unveiled at the Late Breaking Clinical Trial session during the I2 Summit Scientific Meeting at 8:30 am on March 28, 2009, as part of the Annual Meeting of the American College of Cardiology (ACC) being held March 28-31 in Orlando, FL.

The presentation will be made by David Holmes, M.D., principal investigator of the PROTECT AF trial. Hand-on demonstrations of the WATCHMAN technology will be available at the Atritech booth 2857.
The WATCHMAN device continues to be implanted in a limited number of sites while the product is under review at the FDA. For investigational use only, it is intended as an alternative to warfarin therapy for patients with non-valvular atrial fibrillation. Patients with atrial fibrillation are at a significantly greater risk of having a stroke due to embolization of clots that may form in the LAA. Typically these patients require blood thinning medications to prevent these clots from forming in the heart. Current medical therapy requires frequent monitoring and has diet and other drug interactions and increases the risk of bleeding. The WATCHMAN device may be an effective alternative to warfarin for these patients.

For more information: www.atritech.net

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init